Edition:
United States

Tissue Regenix Group PLC (TRX.L)

TRX.L on London Stock Exchange

12.25GBp
20 Sep 2017
Change (% chg)

0.00 (+0.00%)
Prev Close
12.25
Open
12.25
Day's High
--
Day's Low
--
Volume
0
Avg. Vol
158,417
52-wk High
21.00
52-wk Low
10.65

Chart for

About

Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes... (more)

Overall

Beta: 1.74
Market Cap(Mil.): £142.32
Shares Outstanding(Mil.): 1,161.78
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.38 16.25
EPS (TTM): -- -- --
ROI: -- 2.96 14.87
ROE: -- 4.74 13.89

BRIEF-Tissue Regenix announces fundraising of 40 mln pounds

* Raised gross proceeds of 40 mln stg through placing of 400,000,000 shares of 0.5 pence each at price of 10 pence per share

Jul 21 2017

BRIEF-Tissue Regenix proposes acquisition of Cellright Technologies

* Says conditional acquisition of Cellright Technologies for total consideration of up to $30.0 million

Jul 20 2017

BRIEF-Tissue Regenix says still in talks with Cellright regarding possible acquisition

* Remains in discussions with cellright regarding a possible acquisition of cellright by tissue regenix

May 31 2017

BRIEF-Tissue Regenix confirms discussions with Cellright regarding possible acquisition

* Confirms that it is in discussions with Cellright regarding possible acquisition of Cellright by Tissue Regenix Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

May 19 2017

Earnings vs. Estimates